Business Wire

MA-RHINOSTICS/LVL

14.11.2022 12:01:38 CET | Business Wire | Press release

Share
Rhinostics and LVL technologies Partner to Provide Decapping Solutions for Automated Collection Device Workflows

Rhinostics Inc. is excited to announce an expanded partnership with LVL technologies GmbH, which includes Rhinostics’ reselling of LVL’s decapper instrument and LVL’s distribution of Rhinostics’ automated collection devices in Germany and Austria. By combining the Rhinostics’ sample collection device ingenuity with decapper technology, laboratories can benefit from an instantly scalable automated swab and small volume blood collection processing workflow. Automation breaks through manual bottlenecks during capping and recapping steps so that laboratories can increase throughput and consistency while also decreasing cumbersome steps as well as reagent and labor costs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221114005373/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Rhinostics and LVL technologies Partner to Provide Decapping Solutions for Automated Collection Device Workflows (Photo: Business Wire)

“Today, researchers, clinicians, and patients alike expect more when it comes to sample collection and diagnostic workflows from respiratory pathogens, sexually transmitted infections, genetic testing to cancer biomarkers and much more,” explained Cheri Walker, PhD, President and CEO of Rhinostics. “We’re excited to expand our partnership with LVL, our supplier of high-quality collection tubes to Rhinostics during the pandemic and beyond. The companies have enjoyed a close relationship, and we can now offer a full solution for our customers by launching a customized version of LVL’s robust decapper instrument to the market.”

“We are extremely pleased to expand our partnership with Rhinostics,” said Martin von Lueder, Chief Executive Officer of LVL. “We have watched Rhinostics bring industry changing, purpose-built sample collection devices that are automation-enabled to the market. The LVL decapper instrument is the perfect complement to their consumables, allowing improvements to inefficient swab and blood collection workflows. Additionally, we look forward to offering the Rhinostics products to our customers.”

As part of the partnership, the RHINObot™ has been optimized for use with the RHINOstic® Automated Swab – a patent-pending sample collection device that integrates a unique polypropylene-based swab with an automatable cap.

Nasal, buccal, or vaginal samples may be comfortably collected in a clinical setting or easily self-collected as part of an at-home test kit. After collection, the swab is securely screwed into a small, barcoded transport tube. This transport tube may be shipped without use of viral transport or other media to reduce reagent costs as well as risks of leaking, accidental biohazard exposure, and potential PCR interference due to VTM or other media components. Dry shipment also enables greater sample concentrations to boost confidence in sensitive PCR, next generation sequencing (NGS), ELISA methods, even at very low pathogen levels.

Once in the laboratory, samples may be loaded onto the RHINObot™ for automated decapping and capping of up to 96 samples in less than 1 minute. This hands-free workflow eliminates user variability and reduces labor time by up to 80+% to significantly decrease per-test costs.

The collaborative agreement will include co-promoting the RHINOstic® and RHINObot™ solution along with marketing and educational initiatives aimed at making customers aware of the increased convenience, speed, and consistency of the automated workflow.

About Rhinostics

Rhinostics is at the forefront of revolutionizing sample collection. As a spin-out company from Harvard University and Wyss Institute, we are taking a radical new approach to sample collection device design and function. COVID-19 cast light on the urgent need to improve laboratory workflows. Rhinostics was born to meet the moment. Our united mission is to revolutionize laboratory workflows, one purpose-built collection device at a time. We improve sample collection comfort and performance while bringing efficiencies to the laboratory to remove costs and save time compared to traditional sample collection intake. Our groundbreaking technologies include functional design, novel materials, and automation solutions for removing caps and rapid accessioning for hands-free workflows. This enables robust high-throughput assays from start to finish with minimal human intervention, saving time and reducing costs.

Rhinostics’ initial product, the RHINOstic® Automated Swab, aids testing broad diagnostic and life science workflows, in areas like respiratory disease, genomics, STDs, forensics and much more. The company continues to innovate, launching a novel small-volume blood collection device, the VERIstic™, and developing a pipeline of novel sample collection devices that are purpose-built for their application combined with automation enablement. To learn more, visit https://www.rhinostics.com.

About LVL

LVL technologies is a leading global manufacturer of 2D coded tubes in the automation-friendly SBS format, including the necessary technical infrastructure. Based in Crailsheim, Germany, the company supplies organizations and companies in more than 50 countries with high-quality storage tubes for demanding long-term sample storage. Applications range from clinical and veterinary diagnostics and biobanking to compound management and research applications in biotechnology. The latest technical development is the fully automatic TLM 864 Tube Laser Marker.

To learn more, visit https://www.lvl-technologies.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005373/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye